Video

Immunotherapy revolutionizes frontline treatment in advanced RCC

Author(s):

Urology Times staff

Michael E. Hurwitz, MD, PhD, an associate professor of Internal Medicine at the Yale Cancer Center, discusses how immune checkpoint inhibitor–based combination have dramatically altered the frontline treatment paradigm for patients with advanced renal cell carcinoma.

Related Videos
Ellen Cahill, MD, answers a question during a video interview
Male doctor examining patient | Image Credit: © Rawpixel.com - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Ellen Cahill, MD, answers a question during a video interview
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Related Content
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
female doctor talking with male patient
December 22nd 2022

Dr. Katherine Rotker on destigmatizing sexual health

Urology Times staff
"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.
ALLO-316 shows encouraging CAR activity in advanced ccRCC
November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma
November 4th 2024

Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma

Hannah Clarke
“Based on these data, casdatifan has the potential to be a future treatment option for kidney cancer," says Toni K. Choueiri, MD.
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC
October 29th 2024

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

Hannah Clarke Gina Mauro
The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC
September 25th 2024

Pazopanib plus bevacizumab shows promising phase 2 efficacy in ccRCC

Hannah Clarke
"The encouraging results suggest that alternating pazopanib with bevacizumab is a promising treatment regimen for renal cell carcinoma patients in the favorable risk group," says Saby George, MD, FACP.
© 2024 MJH Life Sciences

All rights reserved.